Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Molecular and Cellular Pathobiology

FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth

Greg N. Brooke, Rachel L. Culley, D. Alwyn Dart, David J. Mann, Luke Gaughan, Stuart R. McCracken, Craig N. Robson, Bradley Spencer-Dene, Simon C. Gamble, Sue M. Powell, Robin Wait, Jonathan Waxman, Marjorie M. Walker and Charlotte L. Bevan
Greg N. Brooke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel L. Culley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Alwyn Dart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Mann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luke Gaughan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart R. McCracken
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig N. Robson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradley Spencer-Dene
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon C. Gamble
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sue M. Powell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin Wait
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Waxman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marjorie M. Walker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte L. Bevan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.CAN-10-0874 Published February 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Progression of prostate cancer is highly dependent upon the androgen receptor pathway, such that knowledge of androgen-regulated proteins is vital to understand and combat this disease. Using a proteomic screen, we found the RNA-binding protein FUS/TLS (Fused in Ewing's Sarcoma/Translocated in Liposarcoma) to be downregulated in response to androgen. FUS has recently been shown to be recruited by noncoding RNAs to the regulatory regions of target genes such as cyclin D1, in which it represses transcription by disrupting complex formation. Here we show that FUS has some characteristics of a putative tumor suppressor, as its overexpression promoted growth inhibition and apoptosis of prostate cancer cells, whereas its knockdown increased cell proliferation. This effect was reproducible in vivo, such that increasing FUS levels in tumor xenografts led to dramatic tumor regression. Furthermore, FUS promoted conditions that favored cell-cycle arrest by reducing the levels of proliferative factors such as cyclin D1 and Cdk6 and by increasing levels of the antiproliferative Cdk inhibitor p27. Immunohistochemical analysis revealed that FUS expression is inversely correlated with Gleason grade, demonstrating that patients with high levels of FUS survived longer and were less likely to have bone metastases, suggesting that loss of FUS expression may contribute to cancer progression. Taken together, our results address the question of how androgens regulate cell-cycle progression, by demonstrating that FUS is a key link between androgen receptor signaling and cell-cycle progression in prostate cancer. Cancer Res; 71(3); 914–24. ©2010 AACR.

Footnotes

  • Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org).

  • Received March 11, 2010.
  • Revision received November 5, 2010.
  • Accepted December 9, 2010.
  • ©2010 American Association for Cancer Research.
View Full Text
PreviousNext
Back to top
Cancer Research: 71 (3)
February 2011
Volume 71, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth
Greg N. Brooke, Rachel L. Culley, D. Alwyn Dart, David J. Mann, Luke Gaughan, Stuart R. McCracken, Craig N. Robson, Bradley Spencer-Dene, Simon C. Gamble, Sue M. Powell, Robin Wait, Jonathan Waxman, Marjorie M. Walker and Charlotte L. Bevan
Cancer Res February 1 2011 (71) (3) 914-924; DOI: 10.1158/0008-5472.CAN-10-0874

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth
Greg N. Brooke, Rachel L. Culley, D. Alwyn Dart, David J. Mann, Luke Gaughan, Stuart R. McCracken, Craig N. Robson, Bradley Spencer-Dene, Simon C. Gamble, Sue M. Powell, Robin Wait, Jonathan Waxman, Marjorie M. Walker and Charlotte L. Bevan
Cancer Res February 1 2011 (71) (3) 914-924; DOI: 10.1158/0008-5472.CAN-10-0874
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interests
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Cancer-Associated Alterations in PPP2R4
  • PACE4 Splicing in Cancer
  • SGK1: An Integral Component of the PI3K-Transforming Pathway
Show more Molecular and Cellular Pathobiology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement